Jangho vs Shenyang Xingqi Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Jangho Group Co Ltd (601886.CG)

Q3 202631 Jul – 23 Sep 2026

▲3▼1

Jangho profit jumps, dividends paid, Middle East orders build

First-half contract wins slip on weak interior decoration New construction contracts signed in the first half fell 4.4% from a year earlier to about 13.1 billion yuan. Interior decoration and design work dropped 17.6%, a sign that domestic demand for the company's core fit-out business is soft and could weigh on future revenue.
It is the main demand-side negative and shows the order pipeline shrinking even as profits rose.
First-half profit up 34% with a cash dividend Revenue rose 15.9% to 10.8 billion yuan and net profit climbed 34.3% to 441 million yuan, with second-quarter profit up 88% from the first quarter. The company will pay 0.25 yuan per share in cash, about 283 million yuan, rewarding shareholders.
Strong earnings and a payout are the clearest positive forces on the stock's value.
Saudi transport hub curtain wall contract won A wholly owned subsidiary won a curtain wall contract for the Northwest Transportation Hub in Riyadh worth about 223 million yuan, roughly 1% of 2025 revenue. It shows the company can win work abroad as domestic decoration demand slows.
It is a concrete new overseas order that offsets weak domestic demand.
Dubai W Residences curtain wall contract won A subsidiary won the W Residences curtain wall project in Dubai for about 318 million yuan, roughly 1.5% of 2025 revenue. The company warned no formal contract is signed yet, so the deal and its revenue are not guaranteed.
It adds to the Middle East order book but carries an explicit execution risk.

August 202631 Jul – 23 Sep 2026

▲3▼1

Jangho profit jumps, dividends paid, Middle East orders build

First-half contract wins slip on weak interior decoration New construction contracts signed in the first half fell 4.4% from a year earlier to about 13.1 billion yuan. Interior decoration and design work dropped 17.6%, a sign that domestic demand for the company's core fit-out business is soft and could weigh on future revenue.
It is the main demand-side negative and shows the order pipeline shrinking even as profits rose.
First-half profit up 34% with a cash dividend Revenue rose 15.9% to 10.8 billion yuan and net profit climbed 34.3% to 441 million yuan, with second-quarter profit up 88% from the first quarter. The company will pay 0.25 yuan per share in cash, about 283 million yuan, rewarding shareholders.
Strong earnings and a payout are the clearest positive forces on the stock's value.
Saudi transport hub curtain wall contract won A wholly owned subsidiary won a curtain wall contract for the Northwest Transportation Hub in Riyadh worth about 223 million yuan, roughly 1% of 2025 revenue. It shows the company can win work abroad as domestic decoration demand slows.
It is a concrete new overseas order that offsets weak domestic demand.
Dubai W Residences curtain wall contract won A subsidiary won the W Residences curtain wall project in Dubai for about 318 million yuan, roughly 1.5% of 2025 revenue. The company warned no formal contract is signed yet, so the deal and its revenue are not guaranteed.
It adds to the Middle East order book but carries an explicit execution risk.

Latest31 Jul – 23 Sep 2026

▲3▼1

Jangho profit jumps, dividends paid, Middle East orders build

First-half contract wins slip on weak interior decoration New construction contracts signed in the first half fell 4.4% from a year earlier to about 13.1 billion yuan. Interior decoration and design work dropped 17.6%, a sign that domestic demand for the company's core fit-out business is soft and could weigh on future revenue.
It is the main demand-side negative and shows the order pipeline shrinking even as profits rose.
First-half profit up 34% with a cash dividend Revenue rose 15.9% to 10.8 billion yuan and net profit climbed 34.3% to 441 million yuan, with second-quarter profit up 88% from the first quarter. The company will pay 0.25 yuan per share in cash, about 283 million yuan, rewarding shareholders.
Strong earnings and a payout are the clearest positive forces on the stock's value.
Saudi transport hub curtain wall contract won A wholly owned subsidiary won a curtain wall contract for the Northwest Transportation Hub in Riyadh worth about 223 million yuan, roughly 1% of 2025 revenue. It shows the company can win work abroad as domestic decoration demand slows.
It is a concrete new overseas order that offsets weak domestic demand.
Dubai W Residences curtain wall contract won A subsidiary won the W Residences curtain wall project in Dubai for about 318 million yuan, roughly 1.5% of 2025 revenue. The company warned no formal contract is signed yet, so the deal and its revenue are not guaranteed.
It adds to the Middle East order book but carries an explicit execution risk.

Shenyang Xingqi Pharmaceutical Co Ltd (300573.CS)

Q3 202628 Jul – 11 Sep 2026

▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.
The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.
Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.
The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.
New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.
This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.
Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.
This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

August 202628 Jul – 11 Sep 2026

▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.
The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.
Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.
The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.
New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.
This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.
Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.
This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

Latest28 Jul – 11 Sep 2026

▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.
The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.
Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.
The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.
New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.
This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.
Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.
This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.